A large biobank for acute and emergency medicine
Official title: Acutelines: a Large Biobank Aiming to Improve Early Recognition of Acute Diseases, Contribute to the Development of Personalized Medicine and Optimize Short- and Long-term Outcome
Run by University Medical Center Groningen · NCT04615065 · Data updated 2026-11-12
This study is collecting health information and samples from patients with sudden illnesses in the Emergency Department to see if it can help improve treatments and predict how patients will do.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 35000 (estimated) |
| Sponsor | University Medical Center Groningen Academic / other |
| Locations | 1 site (Groningen) |
| Status | Recruiting |
| Started | September 1, 2020 |
| Main results expected | September 1, 2030 |
| Study ends | September 1, 2030 |
| Registry record updated | June 13, 2024 |
| Trial ID | NCT04615065 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study include patients triaged as red or orange in the Manchester triage system, or those with specific acute conditions such as sepsis or acute kidney injury.
✕Probably not a fit
Patients referred for organ transplantation or those transferred from other hospitals may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Acutelines is a prospective biobank designed to collect extensive data and biomaterials from patients presenting with a variety of acute conditions at the Emergency Department. The initiative aims to enhance the understanding of acute diseases and improve treatment outcomes through interdisciplinary research. By systematically gathering clinical data, imaging, and biomaterials over time, the project seeks to develop personalized treatment strategies and predict patient outcomes more effectively. The study employs a deferred consent procedure to facilitate data collection while ensuring patient rights are respected.
Why it matters
Potential benefit: If successful, this biobank could lead to improved recognition and treatment of acute diseases, ultimately enhancing patient outcomes.
How similar studies have gone: Other studies utilizing biobanks for acute conditions have shown promise, but this specific approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria, at least one of the following: * Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system; * Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS; * Shock * Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria) * Acute kidney injury (AKI) * Anaphylactic reaction * Syncope * Intoxication * Thrombosis * Pulmonary embolism * Bleeding while using anti-coagulant drugs * Gastro-intestinal bleeding * Electrolyte disturbance Exclusion Criteria: * Referred for organ transplantation as recipient * Transfer from other hospital * Accidental contact patient material (i.e. internal work-related accident) While data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories \[red or orange\] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.
Where it's running
-
University Medical Center Groningen
Groningen, Netherlands Recruiting
Study contacts
- Study coordinator: Hjalmar Bouma, MD, PhD
- Email: acutelines@umcg.nl
- Phone: +31 50 361 6161
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulmonary and cardiovascular rehabilitation program for chronic respiratory and heart conditions
This study tests a rehabilitation program that combines exercise for people with chronic lung and heart conditions to see if it helps them feel better and improve their daily activities.
-
Understanding how drugs work in children
This study is trying to find the best and safest doses of certain medications for children and young adults under 21 who are being treated for conditions like COVID-19 and pulmonary arterial hypertension.
-
Wintergreen oil inhalation for shortness of breath in pneumonia patients
Hospitals will test whether inhaling wintergreen essential oil helps relieve dyspnea in adults with pneumonia.
-
Sulbactam-Durlobactam for CRAB infections in real-world care
This real-world study tests whether sulbactam-durlobactam works and is safe for adults with carbapenem-resistant Acinetobacter baumannii infections, compared with other anti-CRAB treatments.
-
Which antibiotic combo is safer for kidneys in serious hospital infections
This trial tests whether vancomycin with piperacillin/tazobactam is gentler on the kidneys than other common broad-spectrum antibiotics for adults with serious infections in the hospital.
-
Catheter ablation plus LAAC vs anticoagulation in frail elderly A-fib patients
This study tests whether adding left atrial appendage closure to ablation is as good as using long-term blood thinners in frail people aged 75 and up with atrial fibrillation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.